VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ARAYAccuray Incorporated
$0.35$41M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksARAYP/E History

ARAY logoAccuray Incorporated (ARAY) P/E Ratio History

Deep Value

Trading at -22.4x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2008–2025

Current P/E (TTM)
-22.4x
-110% vs 5Y avg
5Y Avg P/E
230.1x
Median 117.3x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-22.4x
Min16.6xMedian117.3xMax922.2x
TTM EPS$-0.37
Price$0.35
Earnings YieldN/A
EPS Growth (1Y)90.3%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Accuray Incorporated (ARAY) trades at a price-to-earnings ratio of -22.4x, with a stock price of $0.35 and trailing twelve-month earnings per share of $-0.37.

The current P/E is 110% below its 5-year average of 230.1x. Over the past five years, ARAY's P/E has ranged from a low of 16.6x to a high of 922.2x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, ARAY trades at a 201% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, ARAY trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARAY DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

ARAY Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-22.4vs22.1
-201%
Below Sector
vs. S&P 500
-22.4vs24.4
-192%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 90% EPS growth (1Y)

ARAY P/E vs Peers

Imaging, radiation, and oncology devices peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ISRG logoISRGIntuitive Surgical, Inc.
$144B51.72.37+23%
ABT logoABTAbbott Laboratories
$154B11.6Lowest0.39Best+134%
BSX logoBSXBoston Scientific Corporation
$67B23.3-+55%
MDT logoMDTMedtronic plc
$102B22.0-+31%
SYK logoSYKStryker Corporation
$118B36.62.46+8%
GEHC logoGEHCGE HealthCare Technologies Inc.
$28B13.5-+5%
PHG logoPHGKoninklijke Philips N.V.
$25B25.2-+224%Best
RMD logoRMDResMed Inc.
$27B19.81.14+37%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

ARAY Historical P/E Data (2008–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2025 Q3Mar 31 2025$1.79$0.01303.4x+32%
FY2021 Q3Mar 31 2021$4.95$0.04117.3x-49%
FY2021 Q2-$4.17$0.0855.4x-76%
FY2021 Q1Sep 30 2020$2.40$0.1416.6x-93%
FY2020 Q4-$2.03$0.0368.1x-70%
FY2020 Q3-$1.90$0.0282.6x-64%
FY2011 Q3-$9.02$0.05167.0x-27%
FY2011 Q2Dec 31 2010$6.75$0.1160.9x-74%
FY2011 Q1-$6.22$0.02263.6x+15%
FY2010 Q4Jun 30 2010$6.63$0.04147.7x-36%
FY2010 Q1Sep 30 2009$6.50$0.01855.3x+272%
FY2009 Q4-$6.64$0.01922.2x+301%
FY2008 Q4Jun 30 2008$7.29$0.0982.5x-64%
FY2008 Q3Mar 31 2008$7.81$0.0983.9x-64%
FY2008 Q2Dec 31 2007$15.22$0.07224.8x-2%

Average P/E for displayed period: 230.1x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

18+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ARAY — Frequently Asked Questions

Quick answers to the most common questions about buying ARAY stock.

What is ARAY's P/E ratio?

Accuray Incorporated (ARAY) trailing twelve-month P/E ratio is -22.4x, based on TTM diluted EPS of $-0.37. The 5-year average P/E is 230.1x and the historical range spans 16.6x to 922.2x.

Is ARAY stock overvalued or undervalued?

ARAY trades at -22.4x P/E, below its 5-year average of 230.1x. At the 0th percentile of its historical range (16.6x–922.2x), the stock is priced at a discount to its own history.

Is ARAY stock expensive?

No, ARAY is not expensive on a historical basis. The current P/E of -22.4x is below the 5-year average of 230.1x and sits at the 0th percentile of its valuation range.

What is ARAY's historical P/E range?

Over the past 5 years, ARAY's P/E ratio has ranged from 16.6x to 922.2x, with a median of 117.3x and an average of 230.1x. The current P/E of -22.4x places the stock at the 0th percentile of this range. Full historical data spans 2008–2025.

How does ARAY's P/E compare to the S&P 500?

ARAY trades at -22.4x P/E versus the S&P 500 median of 24.4x. The 192% discount to the market suggests lower growth expectations or perceived higher risk.

How does ARAY's valuation compare to Healthcare peers?

Accuray Incorporated P/E of -22.4x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is ARAY's PEG ratio?

ARAY PEG ratio is N/A, based on a P/E of -22.4x and EPS growth of 90.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is ARAY's earnings yield?

ARAY earnings yield is N/A, the inverse of its -22.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

ARAY P/E Ratio History (2008–2025)

Quarterly valuation multiple from closing price and trailing EPS

Current303.4x
Period Avg230.1x
Range16.6x - 922.2x
Change+35%
15 quartersDec 31, 2007 - Mar 31, 2025